{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:55:40Z","timestamp":1782849340791,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eprac.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:41:15Z","timestamp":1754451675000},"page":"1530-1537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical and Economic Impact of Hybrid Closed-Loop Systems for T1 Diabetes Management in Spain"],"prefix":"10.1016","volume":"31","author":[{"given":"Aesha","family":"Khan-Mir\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Eleni","family":"Syleouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brusaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriel","family":"Nyffeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Chico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Moreno-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar I.","family":"Beato-V\u00edbora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.eprac.2025.08.002_bib1","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13102-023-00695-3","article-title":"Physical activity patterns in type 1 diabetes in Spain: the SED1 study","volume":"15","author":"G\u00f3mez-Peralta","year":"2023","journal-title":"BMC Sports Sci Med Rehabil"},{"issue":"5","key":"10.1016\/j.eprac.2025.08.002_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14766","article-title":"International comparison of glycaemic control in people with type 1 diabetes: an update and extension","volume":"39","author":"Prigge","year":"2022","journal-title":"Diabet Med"},{"issue":"17","key":"10.1016\/j.eprac.2025.08.002_bib4","first-page":"1","article-title":"Patient perspectives on quality of life with uncontrolled type 1 diabetes mellitus: a systematic review and qualitative meta-synthesis","volume":"15","author":"Vanstone","year":"2015","journal-title":"Ont Health Technol Assess Ser"},{"issue":"12","key":"10.1016\/j.eprac.2025.08.002_bib5","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"64","author":"Holt","year":"2021","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.eprac.2025.08.002_bib6","first-page":"642","article-title":"investigators of the studies SED and SED1. Clinical characteristics and management of type 1 diabetes in Spain. The SED1 study","volume":"68","author":"G\u00f3mez-Peralta","year":"2021","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"issue":"14","key":"10.1016\/j.eprac.2025.08.002_bib7","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/dc13-2148","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions","volume":"37","author":"Gubitosi-Klug","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2014.16425","article-title":"Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010","volume":"313","author":"Livingstone","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.002_bib10","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jdiacomp.2018.05.007","article-title":"What are the clinical, quality-of-life, and cost consequences of 30 years of excellent vs. poor glycemic control in type 1 diabetes?","volume":"32","author":"Herman","year":"2018","journal-title":"J Diabetes Complications"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.002_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2013.08.652","article-title":"Direct cost of diabetes mellitus and its complications in Spain. Seccaid Study: Spain estimated cost Ciberdem-Cabimer in diabetes","volume":"16","author":"Crespo","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.eprac.2025.08.002_bib12","author":"Kanavos"},{"issue":"8","key":"10.1016\/j.eprac.2025.08.002_bib13","first-page":"1663","article-title":"Current technologies for managing type 1 diabetes mellitus and their impact on quality of life-a narrative review","volume":"13","author":"Elian","year":"2023","journal-title":"Life (Basel)"},{"issue":"12","key":"10.1016\/j.eprac.2025.08.002_bib14","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1089\/dia.2019.0400","article-title":"Prospective analysis of the impact of commercialized hybrid closed-loop system on glycemic control, glycemic variability, and patient-related outcomes in children and adults: a focus on superiority over predictive low-glucose suspend technology","volume":"22","author":"Beato-V\u00edbora","year":"2020","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.002_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/19322968231185348","article-title":"Real-world evidence analysis of a hybrid closed-loop system","volume":"19","author":"Alwan","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"3","key":"10.1016\/j.eprac.2025.08.002_bib16","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2666-7568(22)00005-8","article-title":"Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study","volume":"3","author":"Boughton","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"12","key":"10.1016\/j.eprac.2025.08.002_bib17","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1089\/dia.2023.0297","article-title":"A European cost-utility analysis of the MiniMed\u2122 780G advanced hybrid closed-loop system versus intermittently scanned continuous glucose monitoring with multiple daily insulin injections in people living with type 1 diabetes","volume":"25","author":"Jendle","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.002_bib18","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(22)00212-1","article-title":"Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study","volume":"10","author":"Choudhary","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.002_bib19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.2337\/dc23-0635","article-title":"Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: a real-world observational study","volume":"46","author":"Crabtree","year":"2023","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2025.08.002_bib20","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jval.2014.07.007","article-title":"Validation of the IMS CORE Diabetes Model","volume":"17","author":"McEwan","year":"2014","journal-title":"Value Health"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2025.08.002_bib21","first-page":"S27","article-title":"Validation of the CORE Diabetes Model against epidemiological and clinical studies","volume":"20","author":"Palmer","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"8","key":"10.1016\/j.eprac.2025.08.002_bib23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.recesp.2014.08.010","article-title":"Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain","volume":"68","author":"Bar\u00f3n Esquivias","year":"2015","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"5","key":"10.1016\/j.eprac.2025.08.002_bib24","first-page":"228","article-title":"Coste-efectividad de rosuvastatina frente a simvastatina, atorvastatina y pitavastatina en pacientes con riesgo cardiovascular alto y muy alto en Espa\u00f1a","volume":"27","author":"Cosin Sales","year":"2015","journal-title":"Clin Investig Arterioscler"},{"issue":"8","key":"10.1016\/j.eprac.2025.08.002_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.recesp.2013.12.016","article-title":"Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain","volume":"67","author":"Delgado","year":"2014","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib26","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1186\/s12913-022-08614-x","article-title":"Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain","volume":"22","author":"Escobar","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib27","first-page":"21","article-title":"Trends in healthcare resource use and expenditure before and after ischaemic stroke","volume":"37","author":"Ribera","year":"2022","journal-title":"A population-based study. Neurologia (Engl Ed)"},{"issue":"5","key":"10.1016\/j.eprac.2025.08.002_bib28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.08.002_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.avdiab.2013.07.007","article-title":"Costes directos de la diabetes mellitus y de sus complicaciones en Espa\u00f1a (Estudio SECCAID: Spain estimated cost Ciberdem-Cabimer in diabetes)","volume":"29","author":"Crespo","year":"2013","journal-title":"Av Diabetol"},{"issue":"11","key":"10.1016\/j.eprac.2025.08.002_bib30","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1093\/ndt\/gfr088","article-title":"Cost analysis of the Spanish renal replacement therapy programme","volume":"26","author":"Villa","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.eprac.2025.08.002_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/13696998.2016.1275651","article-title":"The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI \u226530 kg\/m2","volume":"20","author":"Dilla","year":"2017","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.002_bib34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1534734620903239","article-title":"Cost-effectiveness of platelet-rich plasma for diabetic foot ulcer in Spain","volume":"20","author":"Linertov\u00e1","year":"2021","journal-title":"Int J Low Extrem Wounds"},{"issue":"5","key":"10.1016\/j.eprac.2025.08.002_bib35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10198-010-0244-4","article-title":"Spanish recommendations on economic evaluation of health technologies","volume":"11","author":"L\u00f3pez-Bastida","year":"2010","journal-title":"Eur J Health Econ"},{"issue":"12","key":"10.1016\/j.eprac.2025.08.002_bib36","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.2337\/diacare.25.12.2238","article-title":"Valuing health-related quality of life in diabetes","volume":"25","author":"Coffey","year":"2002","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2025.08.002_bib37","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.numecd.2021.02.028","article-title":"Real-world outcomes with different technology modalities in type 1 diabetes","volume":"31","author":"Beato-V\u00edbora","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"10.1016\/j.eprac.2025.08.002_bib38","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1089\/dia.2022.0449","article-title":"Efficacy, safety, and satisfaction with the Accu-Chek insight with diabeloop closed-loop system in subjects with type 1 diabetes: a multicenter real-world study","volume":"25","author":"Chico","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.002_bib39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/dia.2023.0319","article-title":"12-month efficacy of advanced hybrid closed-loop system in adult type 1 diabetes patients","volume":"26","author":"Nigi","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"10.1016\/j.eprac.2025.08.002_bib40","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.eprac.2025.08.002_bib41","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1007\/s12325-022-02058-9","article-title":"Cost-effectiveness of hybrid closed loop insulin pumps versus multiple daily injections plus intermittently scanned glucose monitoring in people with type 1 diabetes in the Netherlands","volume":"39","author":"Sern\u00e9","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/13696998.2021.1939706","article-title":"Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK","volume":"24","author":"Roze","year":"2021","journal-title":"J Med Econ"},{"issue":"7","key":"10.1016\/j.eprac.2025.08.002_bib43","first-page":"807","article-title":"Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States","volume":"29","author":"Biskupiak","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"10.1016\/j.eprac.2025.08.002_bib44","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1007\/s13300-021-01157-0","article-title":"The cost-effectiveness of an advanced hybrid closed-loop system in people with type 1 diabetes: a health economic analysis in Sweden","volume":"12","author":"Jendle","year":"2021","journal-title":"Diabetes Ther"},{"issue":"5","key":"10.1016\/j.eprac.2025.08.002_bib45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/dia.2023.0455","article-title":"The cost-effectiveness of an advanced hybrid closed-loop system compared to standard management of type 1 diabetes in a Singapore setting","volume":"26","author":"Gardner","year":"2024","journal-title":"Diabetes Technol Ther"},{"issue":"8 suppl","key":"10.1016\/j.eprac.2025.08.002_bib46","first-page":"S55","article-title":"From randomized controlled trials to the real world: putting evidence into context","volume":"67","author":"Blonde","year":"2018","journal-title":"J Fam Pract"},{"issue":"8","key":"10.1016\/j.eprac.2025.08.002_bib47","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.2337\/dc22-2037","article-title":"A road map for peer review of real-world evidence studies on safety and effectiveness of treatments","volume":"46","author":"Winterstein","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2025.08.002_bib48","series-title":"Proceedings of Machine Learning Research","first-page":"2","article-title":"Estimating long-term causal effects from short-term experiments and long-term observational data with unobserved confounding","author":"Graham","year":"2023"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/1475-6773.12310","article-title":"Observing versus predicting: initial patterns of filling predict long-term adherence more accurately than high-dimensional modeling techniques","volume":"51","author":"Franklin","year":"2016","journal-title":"Health Serv Res"},{"issue":"10","key":"10.1016\/j.eprac.2025.08.002_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.20291","article-title":"Use of data-driven methods to predict long-term patterns of health care spending for medicare patients","volume":"3","author":"Lauffenburger","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.eprac.2025.08.002_bib51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40273-018-0749-8","article-title":"Future costs in cost-effectiveness analyses: past, present, future","volume":"37","author":"de Vries","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.eprac.2025.08.002_bib52","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T17:27:35Z","timestamp":1771522055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25009942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1530891X25009942"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.08.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Economic Impact of Hybrid Closed-Loop Systems for T1 Diabetes Management in Spain","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}